Hyperfine, Inc. (HYPR)

Hyperfine, Inc. is a medical device company specializing in portable magnetic resonance imaging (MRI) solutions. Their flagship product, the Swoop Portable MR imaging system, aims to revolutionize point-of-care medical imaging.

47/100 AI Score MCap 75M Vol 377K

Company Overview

CEOMaria Degois-Sainz
Employees111
HeadquartersGuilford, CT, US
IPO Year2021

Hyperfine is revolutionizing medical imaging with its Swoop Portable MR imaging system, addressing unmet needs in point-of-care diagnostics. With a disruptive approach and innovative technology, Hyperfine aims to transform patient care and expand access to critical imaging, despite current profitability challenges.

Investment Thesis

Hyperfine presents a compelling, albeit high-risk, investment opportunity centered on its disruptive Swoop Portable MR imaging system. The potential to revolutionize point-of-care medical imaging and expand access to diagnostics is significant. Key value drivers include increasing adoption of Swoop in hospitals and healthcare facilities, expansion into new clinical applications, and strategic partnerships to broaden market reach. While the company currently operates with a negative profit margin of -378.2%, the high gross margin of 46.1% indicates the potential for profitability as sales volume increases. Successful execution of its commercialization strategy and continued innovation in portable MRI technology are crucial for realizing long-term value. Investors should closely monitor revenue growth, cost management, and progress towards profitability as key indicators of Hyperfine's success.

Key Highlights

  • Market Cap of $0.08B reflects the company's current valuation and growth potential in the medical imaging market.
  • Gross Margin of 46.1% demonstrates the potential for profitability as the company scales its operations.
  • Beta of 1.09 indicates that the stock's volatility is similar to the overall market.
  • The Swoop Portable MR imaging system addresses a critical unmet need in point-of-care medical imaging.
  • The company's innovative technology has the potential to disrupt the traditional MRI market.

Competitors

Strengths

  • Innovative Swoop Portable MR imaging system.
  • Addresses unmet needs in point-of-care imaging.
  • High gross margin potential.
  • Disruptive technology with potential to transform the MRI market.

Weaknesses

  • Currently unprofitable with a negative profit margin.
  • Limited market share compared to established MRI vendors.
  • Reliance on a single product (Swoop).
  • Requires significant capital investment for R&D and commercialization.

Catalysts

  • Upcoming: FDA approvals for new clinical applications of the Swoop system.
  • Ongoing: Increasing adoption of the Swoop system in hospitals and healthcare facilities.
  • Ongoing: Strategic partnerships with key industry players.
  • Ongoing: Development and launch of advanced software and AI features.
  • Upcoming: Positive clinical trial results demonstrating the efficacy of the Swoop system.

Risks

  • Potential: Competition from established MRI vendors with greater resources.
  • Potential: Technological obsolescence if the company fails to innovate.
  • Ongoing: Regulatory hurdles and reimbursement challenges.
  • Potential: Product recalls or safety concerns.
  • Ongoing: The company's current unprofitability and reliance on external funding.

Growth Opportunities

  • Expansion into New Clinical Applications: Hyperfine has the opportunity to expand the use of its Swoop system beyond its initial focus on neurological imaging. Potential applications include cardiac imaging, orthopedic imaging, and pediatric imaging. Each new application represents a significant market opportunity, potentially adding millions of dollars in revenue. The timeline for expansion will depend on clinical trials and regulatory approvals, but the company is actively pursuing these opportunities.
  • Strategic Partnerships: Collaborating with hospitals, healthcare systems, and research institutions can accelerate the adoption of the Swoop system and expand its market reach. Partnerships can provide access to new customer segments, facilitate clinical trials, and enhance the company's credibility. The timeline for securing partnerships is ongoing, with the company actively seeking collaborations to drive growth.
  • International Expansion: The global market for medical imaging is substantial, and Hyperfine has the opportunity to expand its sales and marketing efforts into new geographic regions. Europe, Asia, and Latin America represent significant growth markets for the Swoop system. International expansion will require regulatory approvals and localized marketing strategies, but the potential rewards are substantial.
  • Development of Advanced Software and AI Capabilities: Enhancing the Swoop system with advanced software and artificial intelligence (AI) capabilities can improve image quality, streamline workflows, and provide clinicians with valuable diagnostic insights. AI-powered image analysis tools can assist in the detection of subtle abnormalities and improve diagnostic accuracy. The company is actively investing in software development and AI research to enhance the capabilities of its platform.
  • Direct-to-Consumer Marketing: Hyperfine can explore direct-to-consumer marketing strategies to raise awareness of the Swoop system and its benefits among patients and caregivers. By educating consumers about the advantages of portable MRI, the company can drive demand and increase sales. Direct-to-consumer marketing efforts can include online advertising, social media campaigns, and partnerships with patient advocacy groups.

Opportunities

  • Expansion into new clinical applications.
  • Strategic partnerships with hospitals and healthcare systems.
  • International expansion into new geographic markets.
  • Development of advanced software and AI capabilities.

Threats

  • Competition from established MRI vendors.
  • Technological obsolescence.
  • Regulatory hurdles and reimbursement challenges.
  • Potential for product recalls or safety concerns.

Competitive Advantages

  • Proprietary Swoop Portable MR imaging system technology.
  • First-mover advantage in the portable MRI market.
  • Patents protecting its innovations.
  • Established relationships with hospitals and healthcare providers.

About

Hyperfine, Inc., founded in 2014 and headquartered in Guilford, Connecticut, is a pioneering medical device company focused on transforming the accessibility and practicality of magnetic resonance imaging (MRI). The company's core innovation lies in its Swoop Portable MR imaging system, designed to address the critical need for point-of-care medical imaging. Unlike traditional MRI systems that are large, costly, and require specialized infrastructure, Swoop is portable, affordable, and can be deployed directly to the patient's bedside. This breakthrough technology has the potential to significantly improve patient outcomes, particularly in settings where timely access to imaging is crucial, such as intensive care units, emergency rooms, and remote healthcare facilities. Hyperfine's business model encompasses both hardware sales of the Swoop system and recurring revenue from software and service offerings. By democratizing access to MRI technology, Hyperfine aims to establish itself as a leader in the rapidly evolving field of portable medical imaging, offering a compelling alternative to conventional diagnostic approaches. The company's success hinges on continued innovation, strategic partnerships, and successful commercialization of its disruptive technology.

What They Do

  • Develops and manufactures the Swoop Portable MR imaging system.
  • Provides point-of-care medical imaging solutions.
  • Offers hardware and software services related to its MRI system.
  • Addresses unmet needs in medical imaging through innovative technology.
  • Aims to improve patient outcomes with accessible MRI.
  • Democratizes access to MRI technology.

Business Model

  • Sells the Swoop Portable MR imaging system to hospitals and healthcare facilities.
  • Generates recurring revenue through software subscriptions and service contracts.
  • Offers training and support services to customers.
  • Focuses on point-of-care imaging solutions.

Industry Context

Hyperfine operates within the medical device industry, specifically in the diagnostic imaging segment. The industry is characterized by technological innovation, increasing demand for minimally invasive procedures, and a growing emphasis on point-of-care diagnostics. The global medical imaging market is projected to reach $54.7 billion by 2027, driven by factors such as an aging population, rising prevalence of chronic diseases, and advancements in imaging technologies. Hyperfine's Swoop system competes with traditional MRI systems and other imaging modalities, such as CT and ultrasound. Key competitors include companies like EDAP TMS S.A. (EDAP) and Canon Medical Systems, offering established imaging solutions.

Key Customers

  • Hospitals and medical centers.
  • Intensive care units (ICUs).
  • Emergency rooms (ERs).
  • Remote healthcare facilities.
AI Confidence: 71% Updated: 2/9/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $3M -$11M $0.00
Q2 2025 $3M -$9M $0.00
Q1 2025 $2M -$9M $0.00
Q4 2024 $2M -$10M $0.00

Source: Company filings

Chart & Info

Price Chart

Hyperfine, Inc. (HYPR) stock price: $0.99 (+0.02, +2.18%)

Why Bull

  • •Insider buying suggests confidence in the company's future, indicating that leadership believes in upcoming growth.
  • •Recent social sentiment has turned positive, with discussions highlighting innovative product developments and potential market expansions.
  • •Community views have shifted towards optimism, driven by increased media coverage and interest in medical imaging technology.
  • •The company's strategic partnerships have been well-received, positioning it favorably within the healthcare sector.

Why Bear

  • •Concerns over regulatory challenges in the medical device space have surfaced, causing skepticism among investors.
  • •Recent community discussions have flagged potential supply chain issues that could impact product delivery timelines.
  • •Market perception remains cautious due to the competitive landscape, with several players vying for dominance in medical imaging.
  • •Insider selling activity has raised eyebrows, leading some to question the long-term outlook and commitment of key executives.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
376,929

Rationale

AI-generated technical analysis for HYPR including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Hyperfine, Inc. (HYPR) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for HYPR.

Make a Prediction

Set your price target for Hyperfine, Inc. (HYPR), choose a timeframe, and track your prediction accuracy.

Current price: $0.99

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HYPR.

Price Targets

Wall Street price target analysis for HYPR.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

46.5/100

Score Factors

  • Revenue Growth 4/100

    Revenue grew only 16.8% YoY, suggesting the company is in a slower growth phase.

  • Gross Margin 8/100

    Gross margin at 46.1% indicates good unit economics and healthy profitability per sale.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates HYPR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Hyperfine, Inc. do?

Hyperfine, Inc. is a medical device company specializing in portable magnetic resonance imaging (MRI) technology. Its primary product is the Swoop Portable MR imaging system, designed to provide point-of-care imaging in various clinical settings. Unlike traditional MRI machines, Swoop is mobile, cost-effective, and can be deployed directly to the patient's bedside, addressing the unmet need for accessible and timely medical imaging. The company generates revenue through the sale of Swoop systems and recurring revenue from software and service offerings, aiming to democratize access to MRI technology and improve patient outcomes.

Is HYPR stock a good buy?

HYPR stock represents a high-risk, high-reward investment opportunity. While the company's innovative Swoop system has the potential to disrupt the MRI market, Hyperfine is currently unprofitable with a negative profit margin of -378.2%. The company's high gross margin of 46.1% suggests potential for future profitability as sales increase. Investors should carefully consider the company's growth prospects, competitive landscape, and financial performance before investing. Success depends on the continued adoption of the Swoop system and the company's ability to achieve profitability.

What are the main risks for HYPR?

Hyperfine faces several key risks, including competition from established MRI vendors with greater resources, the potential for technological obsolescence, regulatory hurdles and reimbursement challenges, and the risk of product recalls or safety concerns. The company's current unprofitability and reliance on external funding also pose significant risks. Furthermore, the success of Hyperfine hinges on the adoption of its Swoop system, and any factors that hinder its market acceptance could negatively impact the company's financial performance. Investors should carefully assess these risks before investing in HYPR.

Is HYPR a good stock to buy?

Whether HYPR is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the HYPR MoonshotScore?

The MoonshotScore for HYPR is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is HYPR data updated?

HYPR stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to HYPR is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for HYPR?

Growth catalysts for Hyperfine, Inc. (HYPR) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Hyperfine, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are HYPR's main competitors?

Hyperfine, Inc. (HYPR) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether HYPR has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about HYPR?

Wall Street analyst coverage for HYPR includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is HYPR's market cap?

Market capitalization (market cap) for HYPR is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows HYPR's current market cap alongside enterprise value and other valuation metrics.

How has HYPR stock performed recently?

HYPR's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing HYPR's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in HYPR?

Key risk categories for HYPR include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures HYPR's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling HYPR?

Insider trading activity for HYPR tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is HYPR a good stock for beginners?

Hyperfine, Inc. (HYPR) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is HYPR for first-time investors?

Every stock carries risk, including Hyperfine, Inc. (HYPR). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like HYPR.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Financial data is based on the most recent available information.
  • Future performance is subject to market conditions and company-specific factors.
Data Sources
profilefundamentalsexistingCopy